
  
    
      
        
        Schizophrenia_NNP is_VBZ a_DT devastating_JJ mental_JJ illness_NN and_CC a_DT major_JJ contributor_NN to_TO the_DT global_JJ
        burden_NN of_IN disease_NN ._. In_IN their_PRP$ quest_NN to_TO understand_VB schizophrenia_NN epidemiology_NN ,_, John_NNP McGrath_NNP
        and_CC colleagues_NNS have_VBP previously_RB undertaken_VBN a_DT systematic_JJ review_NN of_IN schizophrenia_NN
        incidence—that_NN is_VBZ ,_, the_DT number_NN of_IN new_JJ cases_NNS diagnosed_VBD each_DT year_NN in_IN a_DT specified_VBN population_NN
        (_( see_VB 
        BMC_NNP Medicine_NNP 2_CD :_: e_SYM 13_CD )_) ._. They_PRP now_RB report_VBP results_NNS from_IN a_DT second_JJ systematic_JJ
        review_NN that_WDT examines_VBZ published_VBN studies_NNS on_IN the_DT prevalence_NN of_IN the_DT disease—i_NN ._. e_SYM ._. ,_, on_IN the_DT number_NN
        of_IN people_NNS who_WP are_VBP suffering_VBG from_IN the_DT disease_NN at_IN a_DT given_VBN time_NN or_CC within_IN a_DT specified_VBN time_NN
        interval_NN ._. (_( Incidence_NNP studies_NNS can_MD suggest_VB risk_VB factors_NNS that_WDT may_MD underlie_VB variations_NNS in_IN the_DT
        disease_NN ._. Prevalence_NNP studies_NNS are_VBP central_JJ to_TO health_NN systems_NNS planning_NN ._. )_)
        Analyzing_NNP a_DT total_NN of_IN 1_CD ,_, 721_CD estimates_NNS from_IN 188_CD studies_NNS and_CC covering_VBG 46_CD countries_NNS ,_, they_PRP
        calculated_VBD the_DT following_VBG median_JJ prevalence_NN estimates_NNS :_: 4_CD ._. 6_CD per_IN 1_CD ,_, 000_CD for_IN point_NN prevalence_NN
        (_( defined_VBN as_IN prevalence_NN during_IN any_DT interval_NN of_IN less_JJR than_IN a_DT month_NN )_) ,_, 3_CD ._. 3_CD for_IN period_NN prevalence_NN
        (_( defined_VBN as_IN prevalence_NN during_IN a_DT period_NN from_IN 1_CD to_TO 12_CD months_NNS )_) ,_, 4_CD ._. 0_CD for_IN lifetime_NN prevalence_NN
        (_( the_DT proportion_NN of_IN individuals_NNS in_IN the_DT population_NN who_WP have_VBP ever_RB manifested_JJ the_DT disease_NN and_CC
        who_WP are_VBP alive_JJ on_IN a_DT given_VBN day_NN )_) ,_, and_CC 7_CD ._. 2_CD for_IN lifetime_NN morbid_NN risk_NN (_( which_WDT attempts_NNS to_TO include_VB
        the_DT entire_JJ lifetime_NN of_IN a_DT birth_NN cohort_NN ,_, both_DT past_JJ and_CC future_JJ ,_, and_CC includes_VBZ those_DT deceased_JJ at_IN
        the_DT time_NN of_IN the_DT survey_NN )_) ._.
        These_DT numbers_NNS are_VBP consistent_JJ with_IN key_JJ policy_NN documents_NNS about_IN point_NN prevalence_NN ,_, but_CC
        suggest_VBP that_IN the_DT 0_CD ._. 5_CD %_NN –_NN 1_CD %_NN estimate_NN for_IN lifetime_NN prevalence_NN given_VBN in_IN many_JJ textbooks_NNS is_VBZ an_DT
        overestimate_NN ._. This_DT estimate_NN ,_, the_DT authors_NNS suggest_VBP ,_, “ is_VBZ another_DT example_NN where_WRB the_DT research_NN
        community_NN needs_VBZ to_TO review_VB their_PRP$ belief_NN systems_NNS in_IN the_DT face_NN of_IN data_NNS ._.” Another_DT often_RB quoted_VBN
        statistic_NN ,_, namely_RB that_DT “ schizophrenia_NN affects_VBZ about_IN one_CD in_IN a_DT hundred_CD” most_RBS sensibly_RB refers_VBZ
        to_TO lifetime_NN morbid_NN risk_NN data_NNS ._. Here_RB as_IN well_RB ,_, the_DT systematic_JJ analysis_NN suggests_VBZ that_IN the_DT
        reality_NN is_VBZ somewhat_RB lower_RBR ,_, and_CC the_DT authors_NNS suggest_VBP that_IN “ if_IN we_PRP wish_VBP to_TO provide_VB the_DT general_JJ
        public_NN with_IN a_DT measure_NN of_IN the_DT likelihood_NN that_IN individuals_NNS will_MD develop_VB schizophrenia_NN during_IN
        their_PRP$ lifetime_NN ,_, then_RB a_DT more_RBR accurate_JJ statement_NN would_MD be_VB that_IN about_IN seven_CD to_TO eight_CD
        individuals_NNS per_IN 1_CD ,_, 000_CD will_MD be_VB affected_VBN ._.”
        The_DT authors_NNS were_VBD surprised_VBN to_TO find_VB no_DT difference_NN in_IN prevalence_NN between_IN males_NNS and_CC
        females_NNS ,_, because_IN their_PRP$ incidence_NN review_NN had_VBD found_VBN a_DT male_JJ /_NN female_JJ risk_NN ratio_NN of_IN 1_CD ._. 4_CD ._. On_IN the_DT
        other_JJ hand_NN ,_, the_DT incidence_NN study_NN had_VBD revealed_VBN a_DT higher_JJR incidence_NN among_IN migrant_NN groups_NNS than_IN
        among_IN native-born_JJ individuals_NNS ,_, and_CC this_DT was_VBD true_JJ for_IN prevalence_NN estimates_NNS as_RB well_RB ._. Compared_VBN
        to_TO economically_RB developed_VBN nations_NNS ,_, the_DT prevalence_NN of_IN schizophrenia_NN is_VBZ lower_JJR in_IN developing_VBG
        nations_NNS ,_, which_WDT is_VBZ consistent_JJ with_IN the_DT literature_NN showing_VBG that_IN the_DT course_NN (_( i_NNP ._. e_SYM ._. ,_, prognosis_NN )_)
        of_IN schizophrenia_NN is_VBZ better_JJR in_IN developing_VBG nations_NNS ._.
        Systematic_NNP reviews_NNS are_VBP secondary_JJ research_NN ,_, where_WRB the_DT object_NN of_IN scrutiny_NN is_VBZ not_RB the_DT
        prevalence_NN of_IN schizophrenia_NN per_IN se_FW but_CC the_DT literature_NN on_IN the_DT topic_NN ,_, and_CC the_DT estimates_NNS in_IN
        this_DT review_NN have_VBP to_TO be_VB treated_VBN accordingly_RB ._. Regardless_RB of_IN exact_JJ numbers_NNS ,_, however_RB ,_, the_DT
        authors_NNS conclude_VBP that_IN “ many_JJ people_NNS with_IN schizophrenia_NN have_VBP persisting_VBG symptoms_NNS ,_, despite_IN the_DT
        best_JJS mix_NN of_IN interventions_NNS we_PRP can_MD offer_VB ._.” It_PRP has_VBZ been_VBN estimated_VBN that_IN current_JJ interventions_NNS
        can_MD at_IN most_JJS reduce_VB 25_CD %_NN of_IN disease_NN burden_NN ,_, thus_RB the_DT authors_NNS conclude_VBP that_IN “ this_DT is_VBZ a_DT
        powerful_JJ argument_NN for_IN investing_VBG in_IN applied_VBN and_CC basic_JJ research_NN ._.”
      
    
  
